Skip to main content

Ashvattha Therapeutics, Inc

Tuesday, February 27, 2024
Ashvattha is a clinical stage company with a transformative nanomedicine technology exclusively licensed from Johns Hopkins University. The nanomedicine, hydroxyl dendrimers (HDs), precisely targets reactive inflammatory cells anywhere in the body. HD therapeutics (HDTs) are a new drug class that targets diseased tissue and are renally excreted intact in humans without observed toxicity. We have clinical programs in ophthalmology, neurology, and inflammation: 1) Phase 2 chronic dosing study of subcutaneous, anti-angiogenic D-4517.2 in wet AMD and DME patients is ongoing. Results expected 1H24. 2) Phase 1/2 study to image neuroinflammation in ALS, MS, PD and AD patients with 18F-OP-801 is ongoing. Results expected 1H24. Imaging results to support HDT development program.
Jeffrey Cleland, Chairman, CEO & President - Ashvattha Therapeutics, Inc.




United States


CEO/Top Company Official

Jeffrey L Cleland, PhD

Lead Product in Development

D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor) is a potent, subcutaneously administered anti-angiogenic nanomedicine that crosses the blood-retinal barrier and selectively targets activated microglia, macrophages, and hypertrophic retinal pigment epithelial cells in the eye. D-4517.2 has the potential to change the current treatment paradigm for neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME) by extending the time between intravitreal anti-VEGF injections via a subcutaneous injection self-administered by the patient. Furthermore, subcutaneous administration of D-4517.2 has the potential to treat both eyes at the same time, a significant benefit for 40-50% of patients with bilateral disease. D-4517.2 is in a Phase 2 chronic dosing clinical trial in subjects with wet AMD or DME.

Development Phase of Primary Product

Phase II

Number Of Unlicensed Products

Products are available to license with exception of China (China rights to D-4517.2, OP-801 and OP-101 held by Huadong Medicine)

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.